Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Impact of an Early Palliative Approach (MAHO2)

15 mai 2019 mis à jour par: Hopital Foch

Impact of an Early and Collegial Consideration of Patients' Vulnerability Comparing to Usual Care. Cluster Randomized Control Study "Mort-A-l'Hôpital 2"

In 2003, MAHO study (Ferrand E, Jabre P, Vincent-Genod C, et al. Circumstances of death in hospitalized patients and nurses' perceptions: French multicenter Mort-a-l'Hôpital survey. Arch Intern Med. 2008 168: 867-875.) evaluated the way 3793 patients died in 200 French hospitals and showed that their conditions of death were not optimal. The 22th April 2005 French Law precised patient's end of life rights with necessity to refrain from any unreasonable obstinacy, the right to refuse treatments and the obligation of a collegial process decision when the patient is not conscious. Since then, studies haven't demonstrate any improvement and found that palliative strategy in France is much less used than in other developed countries.

Aperçu de l'étude

Statut

Résilié

Les conditions

Description détaillée

In 2003, MAHO study evaluated the way 3793 patients died en 200 French hospitals and showed that their conditions of death were not optimal. The 22th April 2005 French Law precised patient's end of life rights with necessity to refrain from any unreasonable obstinacy, the right to refuse treatments and the obligation of a collegial process decision when the patient is not conscious. Since then, studies haven't demonstrate any improvement and found that palliative strategy in France is much less used than in other developed countries.

Principal Objective: To evaluate the impact of an early palliative strategy using vulnerability criteria compared to standard care.

Primary endpoint: Rate of withdraw/withhold of treatment in each group.

Secondary objectives: To evaluate the impact of early recognition of patients' vulnerability on death conditions ; to evaluate this strategy impact according to unit type on length of stay, palliative strategy modalities and caregivers' satisfaction.

Secondary endpoints: Rate of therapeutic involvement reflections ; rate of death following withholding or withdrawing of treatments ; traceability of the level of therapeutic involvement process ; Rate of patients deceased with their relatives next to them ; rate of patients deceased with comfort treatment ; rate of palliative care consultation before death ; rate of asks for euthanasia ; Doctor and nurse's perception of quality of support and death process of the patient

Methods: Prospective, controlled, cluster randomized study of routine care 2 groups:

  • Group A: standard care and practice after 1 day of training
  • Group B: 1 day of training, learning the vulnerability criteria that should induce early thinking about level of therapeutic involvement; web accessed forms will be available to help collegial process, withhold and withdraw decisions traceability, using legal requirements Number of patients to include: To detect a 20% absolute difference in palliative strategy used (30 to 50%), we determined that 5040 patients would provide a power of 80% with the use of a two-sided alpha level of 0.05. Sequential analysis is planned in order to early stop the study in case of efficacy or futility (minimal inclusion: 500 patients)

Inclusion criteria:

All patients hospitalized with at least one of the following vulnerability criteria will be included:

  • Evolutive and symptomatic incurable cancer
  • Aged more than 75 years old and presenting several geriatric syndromes (cognitive disorders, isolation, malnutrition, bedridden more than 12h per day)
  • Neurologic pathology, chronic, with loss of autonomy (Performance Status>3)
  • Final organ failure (heart, lungs, liver, kidney) with loss of autonomy (Performance Status>3)
  • Care refusal and/or expressed will to die or repeated request for help to die

Exclusion criteria:

  • Minors
  • Patients without indication for treatment or surveillance with length of stay inferior to 24h
  • Brain dead patients
  • Not consent patients

Duration: 37 months (28 inclusion months for each center and a follow-up to hospital discharge, death or 9 months if the patient is still hospitalized).

Number of participating centers: 20 centers (28 services) were selected and recruit after training program among centers that did not used a formalized process to initiate level of therapeutic involvement reflection.

Type d'étude

Interventionnel

Inscription (Anticipé)

1200

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Amiens, France, 80000
        • CHU
      • Antony, France, 92160
        • Hopital privé Oncologie Médicale
      • Antony, France, 92160
        • Hôpital Privé Medecine interne
      • Bobigny, France, 93000
        • Hopital Avicenne
      • Boulogne Billancourt, France, 92100
        • Hôpital Ambroise Paré
      • Champcueil, France, 91750
        • Hôpital Georges Clemenceau
      • Dijon, France, 21000
        • CHU
      • Epernay, France, 51200
        • Centre Hospitalier
      • Le Kremlin Bicetre, France, 94270
        • Hôpital Bicêtre
      • Lille, France, 59000
        • CHRU
      • Paris, France, 75010
        • Hopital Lariboisiere Medecine interne
      • Paris, France, 75014
        • Groupe Hospitalier Paris - Saint-Joseph
      • Paris, France, 75014
        • Hopital Cochin Gastro-Enterologie
      • Poitiers, France, 86000
        • Centre Hospitalier Universitaire
      • Roubaix, France, 59100
        • Centre Hospitalier
      • Soissons, France, 02200
        • Centre Hospitalier de Soissons
      • Suresnes, France, 92150
        • Hiopital Foch Néphrologie
      • Suresnes, France, 92150
        • Hopital Foch Cardiologie
      • Suresnes, France, 92150
        • Hopital Foch Chirurgie Urologique
      • Suresnes, France, 92150
        • Hopital Foch Médecine Interne
      • Suresnes, France, 92150
        • Hopital Foch Neurochirurgie
      • Suresnes, France, 92150
        • Hopîtal Foch Urgences
      • Valenciennes, France, 59300
        • CH

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patient more than 18 years old hospitalized for at least 24h and who's prognosis (survival or quality of life) should lead to a palliative approach
  • Patient suffering with at least one of the following vulnerability criteria will be included:

    • Evolutive and symptomatic incurable cancer
    • Aged more than 75 years old and presenting several geriatric syndromes (cognitive disorders, isolation, malnutrition, bedridden more than 12h per day)
    • Neurologic pathology, chronic, with loss of autonomy (Performance Status>3)
    • Final organ failure (heart, lungs, liver, kidney) with loss of autonomy (Performance Status>3)
    • Care refusal and/or expressed will to die or repeated request for help to die
  • No opposition to the use of data collected from the patient or a relative or inclusion in emergency and non-opposition collected offline

Exclusion Criteria:

  • Minors
  • Patients without indication for treatment or surveillance with length of stay inferior to 24h
  • Brain dead patients
  • Not consent patients

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: Usual Practices
the centres applies their usual practices
Autre: Early consideration of vulnerability
Strategy promoting early consideration of patients' vulnerability
One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Rate of withdraw/withhold of treatment in each group
Délai: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
To evaluate the impact of an early palliative strategy using vulnerability criteria compared to standard care.
From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Death conditions
Délai: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital

rate of death relied to a withholding/withdrawing treatment decision, rate relatives present at the time of death, rate of death with comfort drugs, rate of patient/family/relatives interview with a psychologist.

rate of death relied to a withholding/withdrawing treatment decision, rate relatives present at the time of death, rate of death with comfort drugs, rate of patient/family/relatives interview with a psychologist.

From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
Early vulnerability consideration impact on length of stay
Délai: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
total length of stay in the hospital
From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
Palliative strategy modalities
Délai: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
rate of reflections on level of therapeutic involvement
From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
Early vulnerability consideration impact on caregivers' satisfaction
Délai: From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital
Physician and nurses' perceptions about care management and conditions of death, caregivers interview with a psychologist
From hospital admission to death or discharge or 9 months after inclusion if the patient is still in the hospital

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Edouard Ferrand, MD, e.ferrand@hopital-foch.org

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 novembre 2013

Achèvement primaire (Réel)

1 mars 2019

Achèvement de l'étude (Réel)

1 mars 2019

Dates d'inscription aux études

Première soumission

17 février 2016

Première soumission répondant aux critères de contrôle qualité

19 septembre 2016

Première publication (Estimation)

20 septembre 2016

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 mai 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 mai 2019

Dernière vérification

1 mai 2019

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2013/99
  • 2012-A00444-39 (Autre identifiant: ANSM)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner